Objectives: To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC). Patients and Methods: A total of 53 patients (51% chemoresistant) were treated. Twenty-eight received monthly intravenous oxaliplatin (120 mg/m2) and CPT-11 (250 mg/m2) on day 1 and a course of 5-FU; these constituted the IRI250 group. Twenty-five received monthly intravenous oxaliplatin (120 mg/m2), CPT-11 (300 mg/m2) on day 1, and a course of 5-FU (IRI300 group). 5-FU administration was carried out as follows. Those with predominant hepatic disease (n = 32) received an intra-arterial infusion of 5-FU (2,500 mg/day on days 1–4); these were the IA-FU group. The remaining 21 patients received intravenous 5-FU (2,600 mg/m2 plus leucovorin 500 mg/m2 on days 1 and 15); these constituted the IV-FUFOL group. Results: Intention-to-treat response rate was 54.7% (4 CR, 7.5%). Twelve patients (22.5%) had stable disease; only 4 (7.5%) progressed. Median progression-free and overall survivals were 10 and 18 months, respectively. One-year progression-free and overall survival rates were 44.3 and 67.4%, respectively. Grade 3–4 toxicities included diarrhea (45.3% of patients), neutropenia (52.8%), mucositis (13.2%), and emesis (11.3%). There were 3 treatment-related deaths (5.7%), all in the IA-FU/IRI300 subgroup. Severe adverse effects requiring chemotherapy dose adjustment were observed in 67.9% of the patients, with odds ratios 9.04-fold higher in the IA-FU/IRI300 group (95% CI: 1.07–76.20) and 0.23-fold lower in the IV-FUFOL/IRI250 group (95% CI: 0.05–0.97). Conclusion: This combination seems to have substantial activity in ACC. Overall toxicity was unacceptable in the IA-FU and IRI300 groups, with diarrhea and cytopenia constituting the dose-limiting side effects. Tolerance and efficacy profiles achieved with IV oxaliplatin (120 mg/m2 day 1), IV CPT-11 (250 mg/m2 day 1) and IV 5-FU 2.6 g/m2 with IV leucovorin (500 mg/m2 days 1 and 15) was favorable and deserves further investigation.

Keywords:
5-Fluorouracil, Advanced colorectal carcinoma, Irinotecan, Oxaliplatin, Pilot study
1.
Moertel CG: Chemotherapy of gastrointestinal cancer. N Engl J Med 1978;299:1049–1052.
2.
Anonymous: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1994;12:960–969.
3.
Anonymous: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992;10:896–903.
4.
De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997;15:808–815.
5.
Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer – a tale of two drugs: Implications for biochemical modulation. J Clin Oncol 1997;15:368–381.
6.
Levi F, Zidani R, Misset JL: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997;350:681–686.
7.
Anonymous: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-Analysis Group in Cancer. J Clin Oncol 1998;16:301–308.
8.
Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425–432.
9.
Beerblock K, Rinaldi Y, Andre T, Louvet C, Raymond E, Tournigand C, Carola E, Favre R, de Gramont A, Krulik M: Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d’Etude et de Recherche sur les Cancers de l’Ovaire et Digestifs (GERCOD). Cancer 1997;79:1100–1105.
10.
Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, Maillet ML, Goudier MJ, Sire M, Person-Joly MC, Maigre M, Maillart P, Fety R, Burtin P, Lortholary A, Dumesnil Y, Picon L, Geslin J, Gesta P, Danquechin-Dorval E, Larra F, Robert J: Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998;16:1470–1478.
11.
Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell L: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991;9:625–630.
12.
Anonymous: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996;88:252–258.
13.
Hidalgo OF, Gil AC, Campbell W, Hidalgo V, Santos M, Henriquez I, Martin S, Sureda M, Anton LM: Intra-arterial chemotherapy, using the hepatic artery, in metastases of colorectal carcinoma. Rev Med Univ Navarra 1987;31:169–176.
14.
Hidalgo OF, Rebollo J, Vieitez JM, Bilbao I, Tangco E, Abuchaibe O, Pardo F: Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma. Am J Clin Oncol 1993;16:30–33.
15.
Herrmann R: 5-Fluorouracil in colorectal cancer, a never ending story. Ann Oncol 1996;7:551–552.
16.
Bertino JR: Chemotherapy of colorectal cancer: History and new themes. Semin Oncol 1997;24:S18–S18.
17.
Clark JW: Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. Semin Oncol 1997;24:S18–S18.
18.
Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14:709–715.
19.
Pitot HC, Wender DB, O’Connell MJ, Schroeder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Ghosh C, Kirschling RJ, Levitt R, Windschitl HE: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997;15:2910–2919.
20.
Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251–260.
21.
Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;11:909–913.
22.
Ducreux M, Louvet C, Bekradda M, Cvitkovic E: Oxaliplatin for the treatment of advanced colorectal cancer: Future directions. Semin Oncol 1998;25:47–53.
23.
Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N’Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95–98.
24.
Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, de Braud F, Boni C, Benavides M, Dallavalle G, Homerin M: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol 1998;9:105–108.
25.
Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, Nasca S, Nguyen TD, Paillot B, Raoul JL, Duffour J, Fandi A, Dupont-Andre G, Rougier P: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998;16:2739–2744.
26.
Saltz L, Shimada Y, Khayat D: CPT-11 (irinotecan) and 5-fluorouracil: A promising combination for therapy of colorectal cancer. Eur J Cancer Suppl 1996;3:S24–S31.
27.
De Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214–219.
28.
Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel JP, Kunstlinger F, Lecouturier S, Descorps-Declere A: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992;69:893–900.
29.
Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. J Natl Cancer Inst 1994;86:1608–1617.
30.
Bertheault-Cvitkovic F, Jami A, Ithzaki M, Brummer PD, Brienza S, Adam R, Kunstlinger F, Bismuth H, Misset JL, Levi F: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996;14:2950–2958.
31.
Vanhoefer U, Harstrick A, Kohne CH, Achterrath W, Rustum YM, Seeber S, Wilke H: Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 1999;17:907–913.
32.
Harstrick A, Vanhoefer U, Muller C, Achterrath W, Kohne H, Seeber S, Wilke H: Combination of CPT-11 and 5-FU in colorectal cancer: Preclinical rationale and initial phase I results. Proc Ann Meet Am Assoc Cancer Res, 1998.
33.
Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP: Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996;14:2959–2967.
34.
Zeghari-Squalli N, Misset JL, Cvitkovic E, Goldwasser F: Mechanism of the in vitro synergism between SN-38 and oxaliplatin. Proc Ann Meet Am Assoc Cancer Res, 1997.
35.
Lokiec F, Wasserman E, Cvitkovic E, Santoni J, Weill S, Gauzan MF, Misset JL: Final results of the pharmacokinetic study of both CPT-11 (C) and LOHP (L) in combination during a phase I trial in gastrointestinal cancer patients. Proc Annu Meet Am Soc Clin Oncol, 1998.
36.
Cvitkovic E, Wasserman E, Riofrio M, Goldwasser F, Mignard D, Mahjoubi M, Chouaki N, Ouldkaci M, Misset JL: CPT-11/oxaliplatin: Thymidylate synthase independent combination with efficacy in 5-FU refractory colorectal cancer patients. Proc Annu Meet Am Soc Clin Oncol, 1998.
37.
Goldwasser F, Chouaki N, Buthaud X, Riofrio M, Gross M, Tigaud JM, Cvitkovic E, Mignard D, Mahjoubi M, Misset JL: CPT-11/oxaliplatin every two weeks: A phase I study in patients with advanced digestive tumors. Proc Annu Meet Am Soc Clin Oncol, 1998.
38.
Lokiec F, Wasserman E, Santoni J, Mahjoubi M, Misset JL, Cvitkovic E: Pharmacokinetics of the irinotecan/oxaliplatin combination: Preliminary data of an ongoing phase I trial. Proc Annu Meet Am Soc Clin Oncol, 1997.
39.
Ley General de Sanidad, 14/1986, articulo 10.5. Madrid, Ministerio de Salud y Consumo,1986.
40.
Chu E, de Vita V: Principles of cancer management: Chemotherapy; in de Vita V, Hellman S, Rosenberg S (eds): Cancer: Principles and Practice of Oncology, ed 6. Philadelphia, Lippincott Williams and Williams, 2001.
41.
Burris H: Combination chemotherapy; in Perry M (ed): The Chemotherapy Sourcebook, ed 3. Philadelphia, Lippincott Williams and Williams, 2001.
42.
Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Statistics Assoc 1959;53:457–481.
43.
Cox DR: The Analysis of Binary Data. London, Methuen, 1970.
44.
Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509–520.
45.
Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Levi F: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663–669.
46.
Knight RD, Miller LL, Locher P: First-line irinotecan (CPT-11) combined with 5-fluorouracil and leucovorin in patients with untreated metastatic colorectal cancer: Exploratory analysis of efficacy across patient subgroups. Proc Ann Meet Am Soc Clin Oncol, 2000.
47.
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial [published erratum appears in Lancet 2000;355:1372]. Lancet 2000;355:1041–1047.
48.
Bleiberg H, de Gramont A: Oxaliplatin plus 5-fluorouracil: Clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998;25:32–39.
49.
Scheithauer W, Kornek GV, Raderer M, Valencak J, Weinlander G, Hejna M, Haider K, Kwasny W, Depisch D: Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 1999;17:902–906.
50.
Rougier P, van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer [published erratum appears in Lancet 1998;352:1634]. Lancet 1998;352:1407–1412.
51.
Andre T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, Beerblock K, Bouche O, Carola E, Merrouche Y, Morvan F, Dupont-Andre G, de Gramont A: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560–3568.
52.
Andre T, Louvet C, Raymond E, Tournigand C, de Gramont A: Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998;9:1251–1253.
53.
Goldberg RM, Erlichman C: Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. Oncology (Huntingt) 1998;12:59–63.
54.
Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001;19:3801–3807.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.